Abstract
In an effort to develop a rational and practical intraperitoneal (i.p.) recombinant interleukin-2 (rIL-2) program that could be explored in future studies of combination i.p. biological therapy, a pilot trial of single-agent rIL-2 delivered i.p. as a single daily dose on a 5-times-weekly schedule was initiated. With a daily x 5 dose of 8 x 105 units/m2 rIL-2 (Ro 23-6019) only minimal systemic and local toxicity was encountered. This dose is recommended for future trials of combination i.p. biological therapy employing a daily x 5 schedule.
Original language | English |
---|---|
Pages (from-to) | 44-46 |
Number of pages | 3 |
Journal | Regional Cancer Treatment |
Volume | 3 |
Issue number | 1 |
State | Published - 1990 |